Related Experiment Video
Updated: May 26, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
An indirubin derivative, E804, exhibits potent angiosuppressive activity
Yuk-Kit Chan1, Hoi-Hin Kwok, Lai-Sheung Chan
1Department of Biology, Faculty of Science, Hong Kong Baptist University, Hong Kong, China.
Biochemical Pharmacology
|December 20, 2011
Summary
A novel indirubin derivative, E804, demonstrates potent anti-angiogenic effects by inhibiting new blood vessel formation. This compound shows greater efficacy than indirubin-3'-oxime, offering a promising new avenue for treating angiogenesis-dependent diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for solid tumor growth and metastasis.
- Natural product-derived small molecules are a significant source of anti-angiogenic agents.
- Indirubin derivatives, known for antiviral and anti-inflammatory properties, also exhibit angiosuppressive effects.
Purpose of the Study:
- To investigate the anti-angiogenic potential of a novel indirubin derivative, E804.
- To compare the efficacy of E804 with existing compounds like indirubin-3 omino.
- To explore the therapeutic prospects of E804 in angiogenesis-dependent diseases.
Main Methods:
- In vitro assays: human umbilical vein endothelial cell proliferation, migration, and tube formation.
- In vivo models: Matrigel plug assay, directed in vivo angiogenesis assay (DIVAA), aortic ring assay, and zebrafish embryo assay.
- Biochemical analysis: assessment of matrix metalloproteinase-2 and -9 activity.
Main Results:
- E804 significantly inhibited endothelial cell proliferation, migration, and tube formation in vitro.
- E804 demonstrated superior anti-angiogenic activity compared to indirubin-3 omino in vivo.
- E804 suppressed VEGF/bFGF-induced neovascularization, reduced hemoglobin content, and inhibited endothelial cell invasion.
- E804 effectively suppressed ex vivo endothelial cell sprouting and matrix metalloproteinase activity.
- E804 showed dose-dependent inhibition of subintestinal vessel formation in zebrafish embryos.
Conclusions:
- E804 is a potent inhibitor of angiogenesis with enhanced efficacy over indirubin-3 omino.
- E804 represents a promising novel therapeutic candidate for treating diseases characterized by excessive angiogenesis.
- Further research into E804 is warranted to explore its full therapeutic potential.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...